Pharmafile Logo
Pharmafocus logo
Advanced Search

Croda International acquires Solus Biotech

July 4, 2023
Business Services Croda International, Pharmacy, Solus Biotech, acquisition

Croda International has confirmed that it has successfully acquired Solus Biotech, following receipt of approval from the South Korean regulatory …

News
brainss

Sosei Heptares announces first subject dosed in phase 1 trial for schizophrenia therapy

July 3, 2023
Research and Development HTL'149, Neurology, Sosei Heptares, clinical trial, schizophrenia

Sosei Heptares has announced that it has dosed its first patient in its phase 1 trial evaluating HTL0048149 (HTL’149), a …

News
lungs

AstraZeneca shares results from phase 3 trial of datopotamab deruxtecan for NSCLC

July 3, 2023
Medical Communications AstraZeneca, NSCLC, Oncology, clinical trial, datopotamab deruxtecan

AstraZeneca has announced results from its TROPION-Lung01 phase 3 trial for its TROP2-directed antibody drug conjugate, developed in collaboration with …

News

Josef Penninger appointed as new scientific director of Helmholtz Centre for Infection Research

July 3, 2023
Business Services Helmholtz Centre for Infection Research, Josef Penninger, appointment, scientific director

The Helmholtz Centre for Infection Research (HZI), Germany, has appointed Professor Josef Penninger as scientific director. Penninger has previously worked …

Appointment

Kevin Hawkins appointed as Reacta’s head of regulatory affairs

July 3, 2023
Business Services Kevin Hawkins, Reacta, appointment, head of regulatory affairs

Reacta Healthcare, an early-stage food allergy diagnostic company, has announced the appointment of Kevin Hawkins as head of regulatory affairs. …

Appointment
blood-1813410_960_720

FDA approves BioMarin’s Roctavian for adults with severe haemophilia A

June 30, 2023
Medical Communications BioMarin, FDA, Haematology, Roctavian, haemophilia

Global biotechnology company BioMarin Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved Roctavian (valoctocogene roxaparvocec-rvox) …

News
hal-gatewood-_jbclosdsd4-unsplash

Eli Lilly to acquire Sigilon Therapeutics

June 30, 2023
Business Services Chronic Diseases, Eli Lilly, Sigilon, acquisition

Eli Lilly and Sigilon Therapeutics have announced a definitive agreement for Lilly’s acquisition of Sigilon, a biopharmaceutical company focusing on …

News
diabetes

First cellular therapy for patients with type 1 diabetes approved by FDA

June 29, 2023
Medical Communications Diabetes, FDA, Lantidra, Type 1 diabetes, diabetes

The US Food and Drug Administration (FDA) has announced that it has approved Lantidra, the first allogeneic (donor) pancreatic islet …

News

Astellas establishes open innovation hub for tumour microenvironment research

June 29, 2023
Research and Development Astellas Pharma, Mitsui Fudosan, Oncology, open innovation hub, tumour microenvironment

Astellas Pharma and Mitsui Fudosan have announced that Astellas plans to establish a tumour microenvironment (TME) open innovation hub, intended …

News

Anavex Life Sciences and Partex NV Group announce AI-based strategic partnership to enhance patient experience

June 28, 2023
Research and Development AI, Anavex Life Sciences, Partex NV Group, Pharmacy, patient experience

US-based clinical-stage biopharmaceutical company Anavex Life Sciences and German digital pharma platform Partex NV Group have announced a strategic partnership …

News
Bowel cancer screening image

Microba commences phase 1 clinical trial for IBD drug

June 28, 2023
Medical Communications Biotherapeutic, Gastrointestinal tract, Microba, clinical trials, ibd

Australian precision microbiome company Microba has announced that the first participants in its phase 1 inflammatory bowel disease (IBD) clinical …

News

Astellas Pharma shares positive results from phase 3b trial of Fezolinetant for menopause symptoms

June 28, 2023
Medical Communications Astellas Pharma, Pharmacy, clinical trial, fezolinetant, menopause

Astellas Pharma has announced positive topline results from the phase 3b DAYLIGHT clinical trial for fezolinetant, its investigational oral, nonhormonal …

News

Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis

June 28, 2023
Medical Communications Dermatology, NHS, Sotyktu, bristol myers squibb, psoriasis

Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Sotyktu (deucravacitinib) …

News
national-cancer-institute-kluafqlacfw-unsplash

UK nonprofit National Cancer Research Institute to close

June 27, 2023
Medical Communications Cancer, NCRI, National Cancer Research Institute, Oncology, oncology

The National Cancer Research Institute (NCRI) has announced that it is closing after 22 years of advancing cancer research. Established …

News
markus-spiske-dnbtfbnqlrc-unsplash_1

GSK receives FDA Fast Track designation for novel gonorrhoea vaccine

June 27, 2023
Research and Development FDA, GSK, Infections and infestations, Vaccine, fast track designation, gonorrhoea

GSK has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for its investigational vaccine …

News
volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

AstraZeneca’s Xigduo XR approved in China for adults with type-2 diabetes

June 27, 2023
Medical Communications AstraZeneca, China, Diabetes, Xigduo XR, diabetes

AstraZeneca has announced that its Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has now been approved …

News
lungs

Verona Pharma submits FDA New Drug Application for COPD treatment

June 27, 2023
Research and Development COPD, Cardiology, FDA, ensifentrine, new drug application, verona pharma

UK-based Verona Pharma has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug …

News
blood-1813410_960_720

Sanofi shares data about new drug for haemophilia A in paediatric patients

June 26, 2023
Research and Development Haematology, Sanofi, clinical trial, haemophilia a

Sanofi has shared new data from the phase 3 XTEND-Kids study which assessed Altuviiio (Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein) …

News

FDA approves Pfizer’s Litfulo for patients with severe alopecia areata

June 26, 2023
Medical Communications FDA, Litfulo, Pfizer, Pharmacy, alopecia, alopecia areata

Pfizer has announced that the US Food and Drug Administration (FDA) has approved its Litfulo (ritlecitinib) for patients over the …

News

AstraZeneca’s Soliris given EU CHMP recommendation for marketing authorisation

June 26, 2023
Medical Communications AstraZeneca, CHMP, EMA, Immunology, soliris

UK-based biopharmaceutical company AstraZeneca has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) …

News
The Gateway to Local Adoption Series

Latest content

Five Facts about spinal muscular atrophy

January 28, 2026

Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases

January 28, 2026

Everdrone appoints David Borkmann as Senior Medical Advisor

January 28, 2026

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

January 27, 2026

Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer

January 27, 2026